Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning

Journal of Nuclear Medicine

Volumn 46, Issue 9, 2005, Pages 1473-1480

  Ma, Chao ^a   Kuang, Anren ^a   Xie, Jiawei ^b   Ma, Tiekun ^c  

^a SICHUAN UNIVERSITY   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

^c KUNMING UNIVERSITY   (China)

Author keywords

131I; Differentiated thyroid carcinoma; Thyroglobulin; Whole body scanning

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER REGRESSION; DRUG DISTRIBUTION; DRUG UPTAKE; FOLLOW UP; HUMAN; METASTASIS; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; WHOLE BODY SCINTISCANNING; BLOOD; CLINICAL TRIAL; DIAGNOSTIC ERROR; LABORATORY DIAGNOSIS; METHODOLOGY; PRACTICE GUIDELINE; REPRODUCIBILITY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; WHOLE BODY COUNTING;

CLINICAL TRIALS; DIAGNOSTIC ERRORS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; IODINE RADIOISOTOPES; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE-BODY COUNTING;

EID: 27744503694     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hundahl SA, Fleming ID, Fremgen AM, et al. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US 1985-1995. Cancer. 1998;83:2638-2648.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
3. Degrossi OJ, Rozados IB, Damilano S, et al. Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas. Medicina (B Aires). 1991;51:291-295.
4. 131I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092-4097.
5. de Keizer B, Koppeschaar HP, Zelissen PM, et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med. 2001;28:198-202.
6. 131I whole-body scan: comparative study. Clin Endocrinol (Oxf). 2003;58: 421-427.
7. Brendel AJ, Lambert B, Guyot M, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med. 1990;16:35-38.
8. Mertens IJ, De Klerk JM, Zelissen PM, et al. Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. Clin Nucl Med. 1999;24: 346-349.
9. Clark PM, Beckett G. Can we measure serum thyroglobulin? Ann Clin Biochem. 2002;39:196-202.
10. Torrens JI, Burch HB. Serum thyroglobulin measurement: utility in clinical practice. Endocrinol Metab Clin North Am. 2001;30:429-467.
11. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
12. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121-1127.
13. Rubello D, Casara D, Girelli ME, et al. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med. 1992;33:1478-1480.
14. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf). 2003;58:138-140.
15. Pacini F, Mariotti S, Formica N, et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh). 1988;119:373-380.
16. Franke WG, Zophel K, Wunderlich GR, et al. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study. Cancer Detect Prev. 2000;24:524-530.
17. Bellantone R, Lombardi CP, Bossola M, et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. Cancer. 2001;92:2273-2279.
18. Eszlinger M, Neumann S, Otto L, et al. Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. Eur J Endocrinol. 2002;147:575-582.
19. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer. 1988;61:976-981.
20. Feldt-Rasmussen U, Profilis C, Colinet E, et al. Human thyroglobulin reference material (CRM457). Part 1. Assessment of homogeneity, stability and immunoreactivity. Ann Biol Clin (Paris). 1996;54:337-342.
21. Batge B, Dralle H, Padberg B, et al. Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 recurrent or metastatic tumours. Virchows Arch A Pathol Anat Histopathol. 1992;421:521-526.
22. Stojadinovic A, Ghossein RA, Hoos A, et al. Hurtle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19:2616-2625.
23. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-1891.
24. Yoshidi A, Taniguchi S, Hisatome I, et al. Pendrin is an iodine-specific apical porter responsible for iodine efflux from thyroid cells. J Clin Endocrinol Metab. 2002;87:3356-3361.
25. - symporter gene. Endocrinology. 1997;138:4493-4496.
26. Smanik PA, Ryu KY, Theil KS, et al. Expression, exon-intron organization and chromosome mapping of the human sodium iodine symporter. Endocrinology. 1997;138:3555-3558.
27. - symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001;86:2697-2700.
28. Saito T, Endo T, Kawaguchi A, et al. Increased expression of the sodium/iodine transporter in papillary thyroid carcinomas. J Clin Invest. 1998;101: 1296-1300.
29. Bidart JM, Mian C, Lazar V, et al. Expression of pendrin and pendred syndrome (PDS) gene in hunan thyroid tissues. J Clin Endocrinol Metab. 2000;85:2028-2033.
30. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in rediffer-entiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775-782.
31. Aldinger KA, Samaan NA, Ibanez M, et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle giant cell carcinoma of the thyroid. Cancer. 1978;41:2267-2275.
32. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992;52:1369-1371.
33. Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab. 2000;85: 302-308.
34. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radio-iodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629-634.
35. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242-246.
36. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507-3511.
37. Hurley TW, Becker JK, Martinez JR. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. 1994;79:98-105.
38. Ain KB, Dewitt PA, Gardner TG, et al. Low-iodine tube-feeding diet for iodine-131 scanning and therapy. Clin Nucl Med. 1994;19:504-507.
39. Emerson CH, Torres MS. Recombinant human thyroid stimulating hormone: pharmacology, clinical applications and potential uses. BioDrugs. 2003;17:19-38.
40. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115-132.
41. 131I in the detection of differentiated thyroid cancer metastases. Nucl Med Commun. 2000;21:917-923.
42. Haslinghuis LM, Krenning EP, de Herder WW, et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001;24:415-422.
43. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg. 2000;179:457-461.
44. 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000;41:1010-1015.
45. 131I scan. J Nucl Med. 2001;42:71-76.
46. 123I- diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol (Oxf). 2001;55:515-521.
47. Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med. 2002;27:1-8.
48. Braga-Basaria M, Ringel MD. Clinical review 158: beyond radioiodine-a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab. 2003;88:1947-1960.